Click image to enlarge
U-PLEX Combos offer popular panels of biomarkers that have been grouped together for convenient ordering. They have been tested for multiplex compatibility and are fulfilled as a kit. The U-PLEX Obesity Combo 1 (human) contains assays for five analytes (Table 1). Ghrelin, Glucagon and Leptin are traditional metabolic markers; BDNF and FGF-21 are emerging biomarkers that have been associated with metabolic syndrome and obesity. The assays can be used for quantitative measurements in the sample types listed in the "Specifications" tab below, and offer detection limits (LLODs) in the sub- to low pg/mL range.
| Analyte | LLOD - ULOD | units |
| BDNF | 0.72 - 2,000 | pg/mL |
| FGF-21 | 2.8 - 8,230 | pg/mL |
| Ghrelin (total) | 1.7 - 2,710 | pg/mL |
| Glucagon | 0.13 - 156 | pM |
| Leptin | 14 - 47,500 | pg/mL |
-
Specifications
-
-
Kit Contents
-
Documentation
-
References
|
Application(s)
|
|
Metabolic
|
|
|
Analyte(s)
|
|
BDNF, FGF-21, Ghrelin (total), Glucagon, Leptin
|
|
|
Species
|
|
Human
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO SECTOR S 600MM
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex SQ 120
,
MESO SECTOR S 600
|
|
|
U-PLEX Group Compatibility
|
|
Metabolic Group 1
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
Serum, EDTA Plasma, P800 Plasma
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 5-Assay (300 µL)
|
2-8 °C
|
1 each
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
U-PLEX 5-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
Aprotinin
|
2-8 °C
|
1 vial
(50 μL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 5-Assay (1.8 mL)
|
2-8 °C
|
1 each
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
U-PLEX 5-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
Aprotinin
|
2-8 °C
|
1 vial
(250 μL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 5-Assay (1.8 mL)
|
2-8 °C
|
5 each
(1 vial)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
U-PLEX 5-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
5 bottle
(40 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
Aprotinin
|
2-8 °C
|
5 vial
(250 μL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Product Highlights
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Leptin levels are associated with multiple sclerosis risk
|
|
|
|
Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance.
|
|
|
|
A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.
|
|
|
|
Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.
|
|
|
|
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社